|Pulmonary hypertension associated with use of phentermine.|
|Jump to Full Text|
|PMID: 20879069 Owner: NLM Status: MEDLINE|
|Weight-control drugs (known as anorexigens) such as fenfluramine have been linked with pulmonary hypertension in previous reports. In our case, a 29 year old woman was admitted for shortness of breath and was diagnosed with pulmonary hypertension. Three months ago, she had been taking phentermine for five weeks. Other factors that might have contributed to the development of pulmonary hypertension were excluded. With treatment, her symptoms improved. This is the first case that can suggest a possible connection between phenermine single medication with pulmonary hypertension. Phentermine has been considered a relatively safe drug to treat obesity, and further investigation is needed to decide the safety and dosage of phentermine.|
|Woo-Dae Bang; Ji-Ye Kim; Hee-Tae Yu; Sung-Soo Cho; Ji-Yong Jang; Chang-Myung Oh; Boyoung Joung; Hyuk-Jae Chang|
Related Documents :
|17804449 - A usa-based registry for pulmonary arterial hypertension: 1982-2006.
16229789 - Human herpesvirus 8 and pulmonary hypertension.
564519 - Acute experimental emotional stress and natural history of arterial hypertension.
23606929 - Structure and composition of pulmonary arteries, capillaries and veins.
8393399 - Increased plasma levels of atrial natriuretic factor, renin activity, and leukotriene c...
17107989 - Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension.
6172809 - Partial splenic embolization using polyvinyl alcohol foam, dextran, polystyrene, or sil...
1499749 - Bilateral mycotic axillary artery false aneurysms in an intravenous drug user: unsuspec...
15666609 - Duplex-doppler ultrasonography in the detection of lower extremities deep venous thromb...
|Type: Case Reports; Journal Article|
|Title: Yonsei medical journal Volume: 51 ISSN: 1976-2437 ISO Abbreviation: Yonsei Med. J. Publication Date: 2010 Nov|
|Created Date: 2010-09-29 Completed Date: 2011-04-06 Revised Date: 2013-07-03|
Medline Journal Info:
|Nlm Unique ID: 0414003 Medline TA: Yonsei Med J Country: Korea (South)|
|Languages: eng Pagination: 971-3 Citation Subset: IM|
|Cardiology Division, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.|
|APA/MLA Format Download EndNote Download BibTex|
Antihypertensive Agents / therapeutic use
Electrocardiography / methods
Hypertension, Pulmonary / drug therapy*, etiology*
Obesity / drug therapy
Phentermine / adverse effects*, therapeutic use*
Radiography, Thoracic / methods
Sulfonamides / therapeutic use
|0/Antihypertensive Agents; 0/Sulfonamides; 122-09-8/Phentermine; Q326023R30/bosentan|
|Yonsei Med J. 2011 Sep;52(5):869-70
Journal ID (nlm-ta): Yonsei Med J
Journal ID (publisher-id): YMJ
Publisher: Yonsei University College of Medicine
© Copyright: Yonsei University College of Medicine 2010
Received Day: 07 Month: 4 Year: 2010
Revision Received Day: 03 Month: 6 Year: 2010
Accepted Day: 11 Month: 6 Year: 2010
Print publication date: Day: 01 Month: 11 Year: 2010
Electronic publication date: Day: 30 Month: 9 Year: 2010
Volume: 51 Issue: 6
First Page: 971 Last Page: 973
PubMed Id: 20879069
|Pulmonary Hypertension Associated with Use of Phentermine|
|Cardiology Division, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.
Corresponding author: Dr. Hyuk-Jae Chang, Cardiology Division, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, 250 Seongsan-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-8454, Fax: 82-2-393-2041, firstname.lastname@example.org
Obesity is a serious issue that no longer remains a simple problem of aesthetics but signifies a crisis of health. Evidence shows strong connections between mortality from chronic diseases and obesity1,2 that has led to classifying obesity as a treatable disease. One such treatment, appetite-suppressants, known as anorexigens, has been developed and prescribed to patients for many years. However, some of these medications have had a history of harmful side effects with unacceptable mortality and morbidities.3,4
In Europe during 1960s, the after-effects of aminorex has been grossly tied with pulmonary arterial hypertension (PAH). Also, in 1980s there were reports of primary pulmonary hypertension (PPH) and valvulopathy in patients who were treated with fenfluramine.5-9 As a compound, phentermine and fenfluramine have similar structures (Fig. 1), and both compounds have often been prescribed concurrently as an appetite-suppressant when in the 1980s their concurrent usage was reported to have a synergistic effect.10 In time, fenfluramine-phentermine (Fen-Phen) concurrent medication was proven to play a certain role in the development of PPH and valvular heart diseases. However, there has been no reported study that made a case against phentermine single medication to date.
In this case, we report that phentermine single medication causes the same effects of increased prevalence of PAH as those of single fenfluramine or Fen-Phen concurrent medication.
Three month before hospitalization, a 29 year-old woman sought medical help for obesity. She was otherwise healthy and did not smoke cigarettes. There was no family history of pulmonary hypertension. She had not been pregnant and did not take any other medications including oral contraceptives and herbal medications at the time of symptom onset. She weighted 73 kg and was 1.60 m (65 in.) tall. Her body-mass index (the weight in kilograms divided by the square of the height in meters) was 28. Oral medication therapy with phentermine HCl (adipex®) at a dose of 37.5 mg taken every morning was prescribed. The medication continued for 35 days, during which the patient lost 13 kg. After two months since the start of the prescription, the patient began to feel tachycardia and she was admitted for shortness of breath. Laboratory investigation did not show abnormal findings. Chest radiographs showed mild prominence of the right ventricular outflow tract. Right ventricular hypertrophy was shown in electrocardiography (Fig. 2) while echocardiography showed moderate pulmonary hypertension (right ventricular pressure: 63 mmHg) with tricuspid regurgitation and D-shaped left ventricle (LV) (Fig. 3). There was no pericardial effusion. Cardiac catheterization showed moderate pulmonary hypertension and elevated pulmonary vascular resistance. The right ventricular pressure was 70/29 mmHg; the pulmonary-artery pressure was 69/26 mmHg, with a mean of 42 mmHg while resting; the pulmonary-capillary wedge pressure was 7 to 11 mmHg. A heart MRI showed no visible intracardiac shunt or pulmonary thromboembolism. Other studies were performed to rule out various causes of pulmonary hypertension. Liver-function studies showed a mild elevation of alanine aminotransferase. Abdominal ultrasonography revealed no liver abnormalities. Tests for anti-centromere antibodies and anti-HIV Ag were negative.
Bosentan 125 mg was prescribed with diuretics. Radical anticoagulation therapy was administered. The patient was discharged after three days and followed-up with subjective symptom improvement.
Phentermine is an anorexigen which had been approved for short-term use as a treatment of obesity by US FDA in 1959, and has been used since. Phentermine stimulates the secretion of noradrenalin in the central nervous system, and suppresses appetite by regulatingthe β-adrenergic receptors.11 When phentermine and fenfluramine combination treatment was reported to have a synergistic effect on the dopamine and serotonin release in the rat brain,10 Fen-Phen treatment became the mainstay of anorexin treatment of the 1980s. However, this combination treatment was suggested to have strong ties with PAH and valvular heart disease while fenfluramine single medication was also reported with the same side-effects that in November 1997 the US FDA banned the prescription of fenfluramine altogether. However, to date, the FDA still allows the short term use of phentermine. In the 2000 report by Rich, et al.,12 concerning the surveillance data on anorexigens and pulmonary hypertension, the only drug that had a meaningfully causal relationship with PPH amongst antidepressants, anorexigens, and amphetamines was fenfluramines. So far, there exists very few cases and no controlled studies suggesting a connection between PPH and the use of other appetite suppressants such as phentermine.13,14
A concrete evaluation on the safety of phentermine single treatment is still unavailable and there has not been a reported case since 2000.15 However, there had been studies in the 1990s that raised suspicions that phentermine might have similar correlations with PAH as with fenfluramine. In one study, fenfluramine-like medications were suggested to increase the risk of PPH via affecting serotonin [5-Hydroxytryptamine (5-HT)] transporters.16
Rothman, et al.17 reported that some medications known to increase the risk of PPH (e.g., aminorex, fenfluramine, and chlorphentermine) are 5-HT transporter substrates. The role of 5-HT transporters in the development of PAH has been well-evaluated. 5-HT transporter substrates are translocated into pulmonary cells where, depending on the degree of drug retention, their intrinsic toxicity, and individual susceptibility, PPH may develop as a response to concentrations of these drugs or metabolites. According to Rothman, the duration and dosage of the drug also had a direct relationship with the increase in the relative risk of PAH after treatment. If this evidence can be supported by a considerable number of clinical cases, the FDA must amend its decision to allow the usage of a drug that is now in use without safe guidelines. The current Physician's Desk Reference (PDR) guideline allows phentermine for a duration of 3-6 weeks; however, in our case, the patient had developed PAH with 5 weeks of medication.
In summary, we propose that the usage of phentermine might be associated with PAH by presenting the above case. Although phentermine has been considered a safe drug for obesity, further study should be underway to establish safety and dosage of phentermine.
The authors have no financial conflicts of interest.
|1.||Flegal KM,Graubard BI,Williamson DF,Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesityJAMAYear: 20072982028203717986696|
|2.||Calle EE,Thun MJ,Petrelli JM,Rodriguez C,Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adultsN Engl J MedYear: 19993411097110510511607|
|3.||Mark EJ,Patalas ED,Chang HT,Evans RJ,Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermineN Engl J MedYear: 19973376026069271482|
|4.||Dillon KA,Putnam KG,Avorn JL. Death from irreversible pulmonary hypertension associated with short-term use of fenfluramine and phentermineJAMAYear: 199727813209343461|
|5.||Schembre DB,Boynton KK. Appetite-suppressant drugs and primary pulmonary hypertensionN Engl J MedYear: 1997336510511 author reply 512-3. 9019649|
|6.||Goldstein SE,Levy Y,Shoenfeld Y. [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants]HarefuahYear: 199813548949256810911459|
|7.||Tellier P. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifactsAnn Med Interne (Paris)Year: 200115242943611965083|
|8.||Weissman NJ. Appetite suppressants and valvular heart diseaseAm J Med SciYear: 200132128529111307869|
|9.||Sachdev M,Miller WC,Ryan T,Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studiesAm Heart JYear: 20021441065107312486432|
|10.||Wellman PJ,Maher TJ. Synergistic interactions between fenfluramine and phentermineInt J Obes Relat Metab DisordYear: 19992372373210454106|
|11.||Roth JD,Rowland NE. Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in ratsPsychopharmacology (Berl)Year: 1998137991069631962|
|12.||Rich S,Rubin L,Walker AM,Schneeweiss S,Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertensionChestYear: 200011787087410713017|
|13.||Schnabel KH,Schulz V,Busch S,Just H. [Drug-induced primary vascular pulmonary hypertension. Contribution to its etiology and clinical course]Med WeltYear: 19762713001303933821|
|14.||Backmann R,Dengler H,Gahl K,Greiser E,Jesdinsky HJ,Loogen F. [Primary pulmonary hypertension. Report of the Commission of the German Society for Research on Blood Circulation]Verh Dtsch Ges KreislaufforschYear: 1972381341414663536|
|15.||Haddock CK,Poston WS,Dill PL,Foreyt JP,Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trialsInt J Obes Relat Metab DisordYear: 20022626227311850760|
|16.||Eddahibi S,Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesisRespir ResYear: 20023911806844|
|17.||Rothman RB,Ayestas MA,Dersch CM,Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertensionCirculationYear: 199910086987510458725|
Keywords: Phentermine, pulmonary hypertension.
Previous Document: Analysis of hospital disaster in South Korea from 1990 to 2008.
Next Document: Spontaneous rupture of a functioning adrenocortical carcinoma.